APA (7th ed.) Citation

Younossi, Z. M., Stepanova, M., Racila, A., Henry, L., Labriola, D., Taub, R., & Nader, F. (2025). Health-related quality of life (HRQL) assessments in a 52-week, double-blind, randomized, placebo-controlled phase III study of resmetirom (MGL-3196) in patients with metabolic dysfunction-associated steatohepatitis (MASH) and fibrosis. Hepatology (Baltimore, Md.), 81(4), 1318-1327. https://doi.org/10.1097/HEP.0000000000001084

Chicago Style (17th ed.) Citation

Younossi, Zobair M., Maria Stepanova, Andrei Racila, Linda Henry, Dominic Labriola, Rebecca Taub, and Fatema Nader. "Health-related Quality of Life (HRQL) Assessments in a 52-week, Double-blind, Randomized, Placebo-controlled Phase III Study of Resmetirom (MGL-3196) in Patients with Metabolic Dysfunction-associated Steatohepatitis (MASH) and Fibrosis." Hepatology (Baltimore, Md.) 81, no. 4 (2025): 1318-1327. https://doi.org/10.1097/HEP.0000000000001084.

MLA (9th ed.) Citation

Younossi, Zobair M., et al. "Health-related Quality of Life (HRQL) Assessments in a 52-week, Double-blind, Randomized, Placebo-controlled Phase III Study of Resmetirom (MGL-3196) in Patients with Metabolic Dysfunction-associated Steatohepatitis (MASH) and Fibrosis." Hepatology (Baltimore, Md.), vol. 81, no. 4, 2025, pp. 1318-1327, https://doi.org/10.1097/HEP.0000000000001084.